Literature DB >> 11758678

Variable clinical presentation in lysosomal storage disorders.

M Beck1.   

Abstract

Extensive clinical heterogeneity is seen in lysosomal storage disorders, regarding the age of onset and severity of symptoms, the organs involved, and effects on the central nervous system. A broad phenotypic spectrum is seen, for example, in mucopolysaccharidosis type I (Hurler/Scheie disease), Gaucher disease, the several forms of GM2-gangliosidosis and the different manifestations of beta-galactosidase deficiency (GM1-gangliosidosis and Morquio disease type B). Variable clinical expression of the same enzyme defect is not well understood. The presence of different mutations is only part of the explanation, as intrafamilial variability is observed in many cases. Other mechanisms, for example the effect of specific activators, may also have an influence on phenotype.

Entities:  

Mesh:

Year:  2001        PMID: 11758678     DOI: 10.1023/a:1012463605992

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  17 in total

Review 1.  Type 2 gaucher disease: an expanding phenotype.

Authors:  N Tayebi; D L Stone; E Sidransky
Journal:  Mol Genet Metab       Date:  1999-10       Impact factor: 4.797

2.  Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease.

Authors:  P Leinekugel; S Michel; E Conzelmann; K Sandhoff
Journal:  Hum Genet       Date:  1992-03       Impact factor: 4.132

3.  Activity of glucocerebrosidase in extracts of different cell types from type 1 Gaucher disease patients.

Authors:  M C Sa Miranda; J M Aerts; R Pinto; A Fontes; L W de Lacerda; S van Weely; J Barranger; J M Tager
Journal:  Clin Genet       Date:  1990-09       Impact factor: 4.438

4.  Morquio disease, type B: activation of GM1-beta-galactosidase by GM1-activator protein.

Authors:  E Paschke; H Kresse
Journal:  Biochem Biophys Res Commun       Date:  1982-11-30       Impact factor: 3.575

5.  Faulty association of alpha- and beta-subunits in some forms of beta-hexosaminidase A deficiency.

Authors:  A d'Azzo; R L Proia; E H Kolodny; M M Kaback; E F Neufeld
Journal:  J Biol Chem       Date:  1984-09-10       Impact factor: 5.157

6.  Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease.

Authors:  M C Patterson; M Horowitz; R B Abel; J N Currie; K T Yu; C Kaneski; J J Higgins; R R O'Neill; P Fedio; A Pikus
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

7.  The human GM2 activator protein. A substrate specific cofactor of beta-hexosaminidase A.

Authors:  E M Meier; G Schwarzmann; W Fürst; K Sandhoff
Journal:  J Biol Chem       Date:  1991-01-25       Impact factor: 5.157

8.  Molecular characterisation of type 1 Gaucher disease families and patients: intrafamilial heterogeneity at the clinical level.

Authors:  O Amaral; A M Fortuna; L Lacerda; R Pinto; M C Sa Miranda
Journal:  J Med Genet       Date:  1994-05       Impact factor: 6.318

9.  Morquio's disease type B (beta-galactosidase deficiency) in three siblings.

Authors:  M Beck; E M Petersen; J Spranger; P Beighton
Journal:  S Afr Med J       Date:  1987-11-21
View more
  13 in total

1.  Tay-Sachs disease: a novel mutation from India.

Authors:  Daisy Khera; Joseph John; Kuldeep Singh; Mohammed Faruq
Journal:  BMJ Case Rep       Date:  2018-12-13

2.  Short-incubation mass spectrometry assay for lysosomal storage disorders in newborn and high-risk population screening.

Authors:  Thomas P Mechtler; Thomas F Metz; Hannes G Müller; Katharina Ostermann; Rene Ratschmann; Victor R De Jesus; Bori Shushan; Joseph M Di Bussolo; Joseph L Herman; Kurt R Herkner; David C Kasper
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-09-24       Impact factor: 3.205

3.  Towards a selected reaction monitoring mass spectrometry fingerprint approach for the screening of oligosaccharidoses.

Authors:  John Sowell; Tim Wood
Journal:  Anal Chim Acta       Date:  2010-12-07       Impact factor: 6.558

4.  Newborn screening for lysosomal diseases: current status and potential interface with population medical genetics in Latin America.

Authors:  Roberto Giugliani
Journal:  J Inherit Metab Dis       Date:  2012-01-10       Impact factor: 4.982

Review 5.  Human-Induced Pluripotent Stem Cell-Based Modeling of Cardiac Storage Disorders.

Authors:  Bradley C Nelson; Sherin I Hashem; Eric D Adler
Journal:  Curr Cardiol Rep       Date:  2017-03       Impact factor: 2.931

Review 6.  Diffusion-weighted MR imaging in leukodystrophies.

Authors:  Zoltan Patay
Journal:  Eur Radiol       Date:  2005-07-15       Impact factor: 5.315

7.  Predictors of growth patterns in children with mucopolysaccharidosis I after haematopoietic stem cell transplantation.

Authors:  Stefanie Maier; Miroslav Zivicnjak; Lorenz Grigull; Julia B Hennermann; Charlotte Aries; Britta Maecker-Kolhoff; Martin Sauer; Anibh M Das; Rita Beier
Journal:  JIMD Rep       Date:  2022-04-26

8.  Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice.

Authors:  Melita Dvorak-Ewell; Dan Wendt; Chuck Hague; Terri Christianson; Vish Koppaka; Danielle Crippen; Emil Kakkis; Michel Vellard
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

9.  Altered expression of β-galactosidase-1-like protein 3 (Glb1l3) in the retinal pigment epithelium (RPE)-specific 65-kDa protein knock-out mouse model of Leber's congenital amaurosis.

Authors:  Joane Le Carré; Daniel F Schorderet; Sandra Cottet
Journal:  Mol Vis       Date:  2011-05-07       Impact factor: 2.367

10.  The NCS-LSD cohort study: a description of the methods and analyses used to assess the long-term effectiveness of enzyme replacement therapy and substrate reduction therapy in patients with lysosomal storage disorders.

Authors:  W E Henley; L J Anderson; K M Wyatt; V Nikolaou; R Anderson; S Logan
Journal:  J Inherit Metab Dis       Date:  2014-02-12       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.